We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nyxoah (NYXH - Free Report) recently announced that the CY2026 Hospital Outpatient Prospective Payment System (“HOPPS”) and Ambulatory Surgery Center (“ASC”) Rule has been finalized by the U.S. Centers for Medicare & Medicaid Services (“CMS”). As per the final rule, the code used for all Genio hypoglossal nerve stimulation (HGNS) implants — CPT Code 64568 — has been assigned to New Technology Ambulatory Payment Classification (“APC”) 1580 by the CMS. The newly assigned code significantly increases the reimbursement rates for procedures done using Genio implants.
The Genio implant is approved as a treatment for obstructive sleep apnea (OSA) through neuromodulation. Nyxoah first received the CE mark for the device in 2019 following the successful completion of the BLAST OSA study, gaining commercialization authorization in Europe. This was followed by the expansion of Genio implants’ therapeutic indications to include Complete Concentric Collapse (“CCC”) patients in Europe. The CE mark for CCC patients was granted following the successful completion of the BETTER SLEEP study.
NYXH gained FDA approval for Genio implants in August this year following the successful completion of the DREAM IDE study. However, the FDA approval is for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.
Share Price Performance
Nyxoah’s shares have lost 40% so far this year against the industry’s gain of 12.8%. The S&P 500 Index has risen 19% in the same period.
Image Source: Zacks Investment Research
Although shares of NYXH have lost significantly in 2025, the increase in reimbursement rates for Genio implants in the United States may boost prospects for the company in 2026. A rise in reimbursement rates is likely to drive broader adoption, increased procedural throughput and expansion across Medicare-heavy institutions.
More Details on CMS Rule
The new rule raises reimbursement rates for CPT 64568 by 48% from 2025 levels, bringing the rate to roughly $45,000 for hospital outpatient departments. The new 2026 reimbursement rate for the ASC facility, at $42,373, reflects a 58% increase compared with 2025.
Covering all CPT 64568 procedures, including Genio, these updates improve the economic viability of adopting this therapy in U.S. outpatient and ambulatory settings.
Nyxoah noted that the Genio single-incision procedure is well-suited for the ASC environment, and that the increase in ASC reimbursement rates creates new opportunities for therapy expansion and site-of-service diversification.
The significant hike in rates by the CMS for Genio procedures also reinforces the growing recognition of hypoglossal nerve stimulation as a high-value therapy for OSA.
Some better-ranked stocks in the broader medical space areBoston Scientific Corporation (BSX - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Cardinal Health (CAH - Free Report) .
Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 16.4%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.36%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have gained 13.7% compared with the industry’s 5.8% growth so far this year.
IDEXX, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13%. IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.12%.
IDEXX’s shares have gained 82.1% compared with the industry’s 5.8% gain so far this year.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.9%. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.36%.
Cardinal Health has rallied 79.5% compared with the industry’s 15.6% gain so far this year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Nyxoah Gains Favorable CMS Reimbursement Ruling for Genio System
Key Takeaways
Nyxoah (NYXH - Free Report) recently announced that the CY2026 Hospital Outpatient Prospective Payment System (“HOPPS”) and Ambulatory Surgery Center (“ASC”) Rule has been finalized by the U.S. Centers for Medicare & Medicaid Services (“CMS”). As per the final rule, the code used for all Genio hypoglossal nerve stimulation (HGNS) implants — CPT Code 64568 — has been assigned to New Technology Ambulatory Payment Classification (“APC”) 1580 by the CMS. The newly assigned code significantly increases the reimbursement rates for procedures done using Genio implants.
The Genio implant is approved as a treatment for obstructive sleep apnea (OSA) through neuromodulation. Nyxoah first received the CE mark for the device in 2019 following the successful completion of the BLAST OSA study, gaining commercialization authorization in Europe. This was followed by the expansion of Genio implants’ therapeutic indications to include Complete Concentric Collapse (“CCC”) patients in Europe. The CE mark for CCC patients was granted following the successful completion of the BETTER SLEEP study.
NYXH gained FDA approval for Genio implants in August this year following the successful completion of the DREAM IDE study. However, the FDA approval is for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.
Share Price Performance
Nyxoah’s shares have lost 40% so far this year against the industry’s gain of 12.8%. The S&P 500 Index has risen 19% in the same period.
Image Source: Zacks Investment Research
Although shares of NYXH have lost significantly in 2025, the increase in reimbursement rates for Genio implants in the United States may boost prospects for the company in 2026. A rise in reimbursement rates is likely to drive broader adoption, increased procedural throughput and expansion across Medicare-heavy institutions.
More Details on CMS Rule
The new rule raises reimbursement rates for CPT 64568 by 48% from 2025 levels, bringing the rate to roughly $45,000 for hospital outpatient departments. The new 2026 reimbursement rate for the ASC facility, at $42,373, reflects a 58% increase compared with 2025.
Covering all CPT 64568 procedures, including Genio, these updates improve the economic viability of adopting this therapy in U.S. outpatient and ambulatory settings.
Nyxoah noted that the Genio single-incision procedure is well-suited for the ASC environment, and that the increase in ASC reimbursement rates creates new opportunities for therapy expansion and site-of-service diversification.
The significant hike in rates by the CMS for Genio procedures also reinforces the growing recognition of hypoglossal nerve stimulation as a high-value therapy for OSA.
Nyxoah SA Price
Nyxoah SA price | Nyxoah SA Quote
Nyxoah’s Zacks Rank & Key Picks
Currently, NYXH carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space areBoston Scientific Corporation (BSX - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Cardinal Health (CAH - Free Report) .
Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 16.4%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.36%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have gained 13.7% compared with the industry’s 5.8% growth so far this year.
IDEXX, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13%. IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.12%.
IDEXX’s shares have gained 82.1% compared with the industry’s 5.8% gain so far this year.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.9%. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.36%.
Cardinal Health has rallied 79.5% compared with the industry’s 15.6% gain so far this year.